Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has selected Eurofins Discovery to conduct initial pharmacology testing for its co-lead aminoindane series as part of its New Chemical Entity (NCE) pre-clinical program. This collaboration marks a significant milestone in Awakn's mission to develop next-generation therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (AUD).
The NCE program, developed in partnership with Graft Polymer (UK) Plc, aims to create a new class of therapeutics for trauma-related mental health disorders, such as Post-Traumatic Stress Disorder (PTSD). This condition affects approximately 13 million adults in the U.S. and 20 million collectively in the US, UK, and key European markets.
Prof. David Nutt, Awakn's Chief Research Officer, expressed confidence that this collaboration will accelerate their path to delivering groundbreaking treatments. CEO Anthony Tennyson emphasized the potential impact of the NCE program for patients across North America and beyond.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) ha selezionato Eurofins Discovery per condurre i primi test di farmacologia per la sua serie di aminoindani co-lead, nell'ambito del programma pre-clinico per Nuovi Enti Chimici (NCE). Questa collaborazione rappresenta una tappa significativa nella missione di Awakn di sviluppare terapie di nuova generazione per disturbi legati all'uso di sostanze e problemi di salute mentale, con un focus immediato sul Disturbo da Uso di Alcol (AUD).
Il programma NCE, sviluppato in partnership con Graft Polymer (UK) Plc, mira a creare una nuova classe di terapie per disturbi mentali correlati a traumi, come il Disturbo da Stress Post-Traumatico (PTSD). Questa condizione colpisce circa 13 milioni di adulti negli Stati Uniti e 20 milioni complessivamente negli Stati Uniti, Regno Unito e nei principali mercati europei.
Il Prof. David Nutt, Chief Research Officer di Awakn, ha espresso fiducia che questa collaborazione accelererà il loro percorso verso la realizzazione di trattamenti innovativi. Il CEO Anthony Tennyson ha sottolineato il potenziale impatto del programma NCE per i pazienti in tutto il Nord America e oltre.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) ha seleccionado Eurofins Discovery para realizar pruebas iniciales de farmacología para su serie co-líder de aminoindanos como parte de su programa preclínico de Nuevas Entidades Químicas (NCE). Esta colaboración marca un hito significativo en la misión de Awakn de desarrollar terapias de nueva generación para trastornos por consumo de sustancias y problemas de salud mental, con un enfoque inmediato en el Trastorno por Consumo de Alcohol (AUD).
El programa NCE, desarrollado en asociación con Graft Polymer (UK) Plc, tiene como objetivo crear una nueva clase de terapias para trastornos mentales relacionados con trauma, como el Trastorno de Estrés Postraumático (PTSD). Esta condición afecta a aproximadamente 13 millones de adultos en EE. UU. y a 20 millones en total en EE. UU., Reino Unido y los principales mercados europeos.
El Prof. David Nutt, Director de Investigación de Awakn, expresó confianza en que esta colaboración acelerará su camino hacia tratamientos innovadores. El CEO Anthony Tennyson enfatizó el impacto potencial del programa NCE para los pacientes en América del Norte y más allá.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF)는 Eurofins Discovery를 선정하여 새로운 화학 물질(NCE) 전임상 프로그램의 일환으로 공동 이끄는 아미노인단 시리즈에 대한 초기 약리학 테스트를 진행합니다. 이 협력은 Awakn의 물질 사용 및 정신 건강 장애를 위한 차세대 치료제 개발이라는 임무에서 중요한 이정표를 나타내며, 알코올 사용 장애(AUD)에 대한 즉각적인 초점을 맞추고 있습니다.
NCE 프로그램은 Graft Polymer (UK) Plc와 협력하여 개발되었으며, 외상 후 스트레스 장애(PTSD)와 같은 외상 관련 정신 건강 장애를 위한 새로운 클래스의 치료제를 창출하는 것을 목표로 합니다. 이 상태는 미국에서 약 1300만 명의 성인과 미국, 영국 및 주요 유럽 시장에서 총 2000만 명에게 영향을 미칩니다.
Awakn의 최고 연구 책임자인 David Nutt 교수는 이 협력이 혁신적인 치료법을 제공하는 데 기여하리라는 자신감을 나타냈습니다. CEO Anthony Tennyson은 NCE 프로그램이 북미 및 그 너머의 환자들에게 미칠 수 있는 잠재적 영향을 강조했습니다.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) a sélectionné Eurofins Discovery pour réaliser des tests pharmacologiques initiaux pour sa série d'aminoindanes co-dirigée dans le cadre de son programme de Nouvelle Entité Chimique (NCE) préclinique. Cette collaboration marque une étape importante dans la mission d'Awakn de développer des thérapies de nouvelle génération pour les troubles liés à l'utilisation de substances et les troubles de la santé mentale, avec un accent à court terme sur le Trouble de l'Usage de l'Alcool (AUD).
Le programme NCE, développé en partenariat avec Graft Polymer (UK) Plc, vise à créer une nouvelle classe de thérapies pour les troubles de la santé mentale liés aux traumatismes, tels que le Trouble de Stress Post-Traumatique (PTSD). Cette condition affecte environ 13 millions d'adultes aux États-Unis et 20 millions au total aux États-Unis, au Royaume-Uni et sur les principaux marchés européens.
Le Prof. David Nutt, directeur de la recherche chez Awakn, a exprimé sa confiance quant au fait que cette collaboration accélérera leur chemin vers des traitements révolutionnaires. Le PDG Anthony Tennyson a souligné l'impact potentiel du programme NCE pour les patients en Amérique du Nord et au-delà.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) hat Eurofins Discovery ausgewählt, um die ersten Pharmakologietests für ihre co-lead Aminoindan-Serie im Rahmen des präklinischen Programms für Neue Chemische Substanzen (NCE) durchzuführen. Diese Zusammenarbeit stellt einen bedeutenden Meilenstein in Awaks Mission dar, neuartige Therapeutika für Substanzmissbrauch und psychische Gesundheitsstörungen zu entwickeln, mit einem kurzfristigen Fokus auf Alkoholabhängigkeit (AUD).
Das NCE-Programm, das in Partnerschaft mit Graft Polymer (UK) Plc entwickelt wurde, zielt darauf ab, eine neue Klasse von Therapeutika für traumabezogene psychische Gesundheitsstörungen wie Posttraumatische Belastungsstörung (PTBS) zu schaffen. Diese Erkrankung betrifft in den USA etwa 13 Millionen Erwachsene und 20 Millionen insgesamt in den USA, Großbritannien und wichtigen europäischen Märkten.
Prof. David Nutt, Chief Research Officer von Awakn, äußerte Zuversicht, dass diese Zusammenarbeit ihren Weg zur Entwicklung bahnbrechender Behandlungen beschleunigen wird. CEO Anthony Tennyson betonte die potenziellen Auswirkungen des NCE-Programms für Patienten in ganz Nordamerika und darüber hinaus.
- Partnership with Eurofins Discovery for pharmacology testing in NCE pre-clinical program
- Collaboration with Graft Polymer (UK) Plc for developing new therapeutics
- Potential market of 20 million adults affected by PTSD in US, UK, and key European markets
- Progress in developing treatments for Alcohol Use Disorder (AUD) and other mental health challenges
- None.
Toronto, Ontario--(Newsfile Corp. - October 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), today announced the selection of Eurofins Discovery to conduct initial pharmacology testing for its co-lead aminoindane series as part of Awakn's New Chemical Entity (NCE) pre-clinical program.
Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, will play a pivotal role in advancing Awakn's pre-clinical research efforts. This testing phase marks a critical milestone in the Company's mission to develop next-generation therapeutics, with the potential to revolutionize treatments for addiction and mental health conditions.
Awakn's NCE program is being developed in partnership with Graft Polymer (UK) Plc ("Graft"), an innovative biotechnology company that specializes in co-developing therapeutics for mental health disorders. This collaboration, initially announced on July 18, 2024, focuses on developing a new class of therapeutics for the potential treatment of trauma-related mental health disorders, such as Post-Traumatic Stress Disorder ("PTSD"), which affects approximately 13 million adults in the U.S. and 20 million collectively in the US, UK and key European markets.
Today's announcement follows Awakn's recent program update from August 28, 2024, and reflects the continued progress and momentum of the NCE program. The initiation of pharmacology testing with Eurofins Discovery underscores Awakn's commitment to advancing its therapeutic pipeline rapidly and efficiently.
Prof. David Nutt, Awakn's Chief Research Officer, commented, "The selection of Eurofins Discovery for this crucial stage of pharmacology testing is a significant step forward in our pre-clinical program. We are confident that this collaboration will accelerate our path to delivering groundbreaking treatments for mental health and addiction disorders."
Anthony Tennyson, CEO of Awakn, added, "Our partnership with Eurofins Discovery is a testament to the progress we're making in developing innovative solutions for AUD and other mental health challenges. We are excited about the potential impact our NCE program could have for patients in need across North America and beyond."
About Awakn Life Sciences Corp.
Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing therapeutics targeting substance use and mental health disorders. Awakn has a near-term focus on AUD, a condition affecting approximately 29 million adults in the US and approximately 40 million in the US and key European markets for which the current standard of care is inadequate. Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels.
www.awaknlifesciences.com | LinkedIn | X (formerly Twitter)
About Eurofins Discovery
Eurofins Discovery supports drug discovery research with over 23,000 products and services developed in 40+ years of industry leadership. Benefit from the strength of our solutions that revolutionize your drug discovery.
Notice Regarding Forward-Looking Information
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.
Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include, but are not limited to: fluctuations in general macroeconomic conditions; the business plans and strategies of the Company; the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; fluctuations in securities markets; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; expectations regarding the size of the addiction market; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.
Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedarplus.ca. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Investor Enquiries:
Anthony Tennyson, CEO, Awakn Life Sciences
anthony.tennyson@awaknlifesciences.com
416-270-9566
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225526
FAQ
What is the purpose of Awakn's partnership with Eurofins Discovery?
What is the focus of Awakn's (AWKNF) NCE program?
How many people are affected by PTSD in Awakn's (AWKNF) target markets?
When did Awakn (AWKNF) announce its partnership with Graft Polymer for the NCE program?
